FDA VRBPAC Makes Recommendations For 2025-2026 Formula for COVID-19 Vaccines
It has been a busy week for FDA-related news. On Tuesday, in an article published in the New England Journal of Medicine, FDA Commissioner Marty Makary, MD, MPH, and Vinay Prasad, MD, MPH, director of the FDA’s Center for Biologics Evaluation and Research (CBER), laid out their plan that will change the bar for how COVID-19 […]
Reviewing Real-World Safety and Efficacy Data on C difficile Therapy Rebyota
Fecal microbiota, live-jslm (Rebyota [RBL]), which is indicated for treatment of recurrent C difficile, has been FDA approved for over 2 years now, and with it comes real-world efficacy and safety data. Paul Feuerstadt, MD, FACG, AGAF, associate clinical professor of Medicine at Yale School of Medicine, has been involved with studies around this therapy […]
Communicable disease threats report, 17-23 May 2025, week 21
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 17-23 May 2025 and includes updates on respiratory virus epidemiology in the EU/EEA, chikungunya virus disease, and mpox. Source link
